MagForce (XTRA:MF6) - Share price, News & Analysis

MF6 fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	5/6
Past Performance	3/6
Financial Health	0/6
Dividends	0/6

MF6 Stock Overview

MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland.

Rewards

Trading at 74.1% below our estimate of its fair value

Earnings are forecast to grow 50.33% per year

Became profitable this year

Risk Analysis

Highly volatile share price over the past 3 months

Has a high level of debt

Large one-off items impacting financial results

Latest financial reports are more than 6 months old

+ 3 more risks

MagForce Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MagForce
Historical stock prices
Current Share Price	€2.03
52 Week High	€4.15
52 Week Low	€1.74
Beta	2.1
1 Month Change	-22.52%
3 Month Change	-15.42%
1 Year Change	-49.38%
3 Year Change	-57.22%
5 Year Change	-74.41%
Change since IPO	-96.83%

Shareholder Returns

	MF6	DE Medical Equipment	DE Market
7D	-0.5%	5.5%	1.2%
1Y	-49.4%	0.2%	-12.2%

Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 0.2% over the past year.

Return vs Market: MF6 underperformed the German Market which returned -12.2% over the past year.

Price Volatility

Is MF6's price volatile compared to industry and market?
MF6 volatility
MF6 Average Weekly Movement	12.8%
Medical Equipment Industry Average Movement	6.5%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	3.5%

Stable Share Price: MF6 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: MF6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1997	34	Ben Lipps	https://www.magforce.com

MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of solid tumors; NanoPlan, a simulation software that helps the treating physicians to define the NanoTherm therapy schedule according to the distribution of the NanoTherm depots in the tumor; and NanoActivator, a magnetic field applicator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.

MagForce Fundamentals Summary

How do MagForce's earnings and revenue compare to its market cap?
MF6 fundamental statistics
Market Cap	€59.81m
Earnings (TTM)	€14.57m
Revenue (TTM)	€1.27m

4.1x

P/E Ratio

47.1x

P/S Ratio

Is MF6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MF6 income statement (TTM)
Revenue	€1.27m
Cost of Revenue	€808.15k
Gross Profit	€461.21k
Other Expenses	-€14.11m
Earnings	€14.57m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Jun 30, 2022

Earnings per share (EPS)	0.49
Gross Margin	36.33%
Net Profit Margin	1,147.78%
Debt/Equity Ratio	86.3%

How did MF6 perform over the long term?

See historical performance and comparison

Valuation

Is MagForce undervalued compared to its fair value and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MF6 (€2.03) is trading below our estimate of fair value (€7.84)

Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: MF6 is good value based on its PE Ratio (4.1x) compared to the German Medical Equipment industry average (31.2x).

PE vs Market: MF6 is good value based on its PE Ratio (4.1x) compared to the German market (17.3x).

Price to Earnings Growth Ratio

PEG Ratio: MF6 is good value based on its PEG Ratio (0.1x)

Price to Book Ratio

PB vs Industry: MF6 is good value based on its PB Ratio (1.9x) compared to the DE Medical Equipment industry average (2.9x).

Future Growth

How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

50.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MF6's forecast earnings growth (50.3% per year) is above the savings rate (-0.05%).

Earnings vs Market: MF6's earnings (50.3% per year) are forecast to grow faster than the German market (7.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MF6's revenue (45.8% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: MF6's revenue (45.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MF6's Return on Equity is forecast to be low in 3 years time (3.2%).

Past Performance

How has MagForce performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

45.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MF6 has a large one-off gain of €24.5M impacting its June 30 2021 financial results.

Growing Profit Margin: MF6 became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: MF6 has become profitable over the past 5 years, growing earnings by 45.2% per year.

Accelerating Growth: MF6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MF6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16%).

Return on Equity

High ROE: MF6's Return on Equity (47.2%) is considered outstanding.

Financial Health

How is MagForce's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: MF6's short term assets (€2.1M) do not cover its short term liabilities (€11.9M).

Long Term Liabilities: MF6's short term assets (€2.1M) do not cover its long term liabilities (€21.6M).

Debt to Equity History and Analysis

Debt Level: MF6's net debt to equity ratio (84.1%) is considered high.

Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if MF6's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if MF6's interest payments on its debt are well covered by EBIT.

Balance Sheet

Dividend

What is MagForce current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MF6 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

9.1yrs

Average management tenure

CEO

Ben Lipps (81 yo)

8.67yrs

Tenure

Dr. Benjamin J. Lipps, also known as Ben, serves as Director and Chief Executive Officer at MagForce USA, Inc. He has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG si...

Leadership Team

Experienced Management: MF6's management team is seasoned and experienced (9.1 years average tenure).

Board Members

Experienced Board: MF6's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/16 00:00
End of Day Share Price	2022/05/16 00:00
Earnings	2021/06/30
Annual Earnings	2020/12/31